Metabolic syndrome and risk of meningioma - population-based case-control analysis

Study type
Protocol
Date of Approval
Study reference ID
16_122
Lay Summary

Metabolic syndrome (MetS) is a medical condition characterised by having at least 3 of the following 4 conditions: high blood pressure, insulin resistance (followed by high blood sugar levels), obesity (excess body fat around the waist) and high cholesterol levels. It affects around 15% of adult Europeans and has been increasing over the past years.
Meningioma is a type of brain cancer that occurs in the cerebral meninges.
One prior study found an increased risk of meningioma in patients suffering from metabolic syndrome, but further studies with larger sample sizes are needed to confirm those results. We therefore propose to conduct a study using the U.K.-based Clinical Practice Research Datalink (CPRD) to analyse the association between metabolic syndrome and the risk of meningioma.

Technical Summary

Using data from the CPRD, we intend to perform a matched case-control analysis to explore the association between metabolic syndrome and risk of meningioma. Cases will be individuals with an incident diagnosis of meningioma between 1995 and 2015. We will match ten control patients to each case on age, sex, calendar time, general practice, and number of years of active history in the CPRD prior to the index date. Relative risks will be estimated by conducting conditional logistic regression analyses to determine odds ratios (ORs) with 95% confidence intervals (CIs) Analyses will be adjusted for various potential confounders.

Health Outcomes to be Measured

The association between metabolic syndrome and risk of meningioma

Collaborators

Christoph Meier - Chief Investigator - University of Basel
Claudia Becker - Collaborator - University of Basel
Corinna Seliger - Collaborator - University of Regensburg
Michael Leitzmann - Collaborator - University of Regensburg
Peter Hau - Collaborator - University of Regensburg
Susan Jick - Collaborator - BCDSP - Boston Collaborative Drug Surveillance Program
Ulrich Bogdahn - Collaborator - University of Regensburg